Emibetuzumab

Emibetuzumab
Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	HGFR
Clinical data
Other names	LY2875358
ATC code	none;
Identifiers
CAS Number	1365287-97-3;
IUPHAR/BPS	7748;
ChemSpider	none;
UNII	MO4K3GDN1I;
Chemical and physical data
Formula	C6356H9810N1694O2014S48
Molar mass	143719.12 g·mol−1

Emibetuzumab (INN^[1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer.^[2] It is in phase II trials for patients with NSCLC^[3]

This drug was developed by Eli Lilly & Company.

References

^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab, American Medical Association.
^ Camidge DR, Moran T, Demedts I, Grosch H, Di Mercurio JP, Mileham KF, et al. "A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC".

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab, American Medical Association.

[3] Camidge DR, Moran T, Demedts I, Grosch H, Di Mercurio JP, Mileham KF, et al. "A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC".

[1]

[2]

[3]